Janux Therapeutics, Inc. JANX
Janux Therapeutics, Inc. (Nasdaq: JANX) is an oncology drug developer. Its lead program, JANX007, is in Phase 1 for metastatic castration-resistant prostate cancer (mCRPC).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| JANX007 | metastatic castration-resistant prostate cancer (mCRPC) | biologic-other | Phase 1 |
| JANX014 | prostate cancer (PSMA-targeted) | biologic-other | Phase 1 |
| JANX013 | prostate cancer (PSMA-targeted) | biologic-other | Phase 1 |
| JANX011 | autoimmune diseases (CD19-ARM) | biologic-other | Phase 1 |
| JANX008 | cancer | biologic-other | Pre-clinical |
Recent results and decisions
- Nov 5, 2026started First patient dosed in Phase 1 study evaluating JANX013 in combination with JANX007 in mCRPC patients.
The first patient has been dosed in the Phase 1 study evaluating JANX013 in combination with JANX007 in patients with mCRPC, representing the first clinical evaluation of Janux's TRACIr platform.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Aktis Oncology, Inc. AKTS
- Adlai Nortye Group Ltd. ANL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.